These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19300249)

  • 21. Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study.
    Kinai E; Komatsu K; Sakamoto M; Taniguchi T; Nakao A; Igari H; Takada K; Watanabe A; Takahashi-Nakazato A; Takano M; Kikuchi Y; Oka S;
    J Neurovirol; 2017 Dec; 23(6):864-874. PubMed ID: 28971376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy.
    Webb KM; Mactutus CF; Booze RM
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):193-203. PubMed ID: 19254168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
    Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
    AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy recommendations for HIV-associated neurocognitive disorders.
    Zirulnik JL
    JAMA; 2008 Dec; 300(21):2482; author reply 2482-3. PubMed ID: 19050186
    [No Abstract]   [Full Text] [Related]  

  • 25. Dementia and neurocognitive disorders due to HIV-1 infection.
    Ances BM; Ellis RJ
    Semin Neurol; 2007 Feb; 27(1):86-92. PubMed ID: 17226745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
    Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
    Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1-associated central nervous system dysfunction.
    Krebs FC; Ross H; McAllister J; Wigdahl B
    Adv Pharmacol; 2000; 49():315-85. PubMed ID: 11013768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.
    Gendelman HE; Gelbard HA
    Curr Opin HIV AIDS; 2014 Nov; 9(6):585-90. PubMed ID: 25226025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of HIV central nervous system persistence on pathogenesis.
    Brew BJ; Barnes SL
    AIDS; 2019 Dec; 33 Suppl 2():S113-S121. PubMed ID: 31790377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV, dementia and antiretroviral drugs: 30 years of an epidemic.
    Manji H; Jäger HR; Winston A
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1126-37. PubMed ID: 23378642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging findings and clinical course.
    Thurnher MM; Schindler EG; Thurnher SA; Pernerstorfer-Schön H; Kleibl-Popov C; Rieger A
    AJNR Am J Neuroradiol; 2000 Apr; 21(4):670-8. PubMed ID: 10782776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.
    Spudich S; González-Scarano F
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007120. PubMed ID: 22675662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders.
    Tyor W; Fritz-French C; Nath A
    J Neurovirol; 2013 Dec; 19(6):515-22. PubMed ID: 24129908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?
    Brew BJ; Clifford DB
    AIDS; 2023 Nov; 37(13):2095-2096. PubMed ID: 37755427
    [No Abstract]   [Full Text] [Related]  

  • 37. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
    Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
    J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 neuroimmunity in the era of antiretroviral therapy.
    Kraft-Terry SD; Stothert AR; Buch S; Gendelman HE
    Neurobiol Dis; 2010 Mar; 37(3):542-8. PubMed ID: 20044002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
    Calcagno A; Barco A; Trunfio M; Bonora S
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):84-91. PubMed ID: 29363025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive Review.
    Borrajo A; Pérez-Rodríguez D; Fernández-Pereira C; Prieto-González JM; Agís-Balboa RC
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.